Goflikicept - TRPHARM
Alternative Names: RPH-104Latest Information Update: 29 Apr 2024
At a glance
- Originator TRPHARM
- Developer R-Pharm; TRPHARM
- Class Analgesics; Anti-inflammatories; Recombinant fusion proteins
- Mechanism of Action Interleukin 1 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Pancreatitis; Pericarditis
- Phase II/III SARS-CoV-2 acute respiratory disease
- Phase II Adult-onset Still's disease; Familial Mediterranean fever; Gouty arthritis; Myocardial infarction; Pain
Most Recent Events
- 29 Apr 2024 Phase-II clinical trials in Adult-onset Still's disease (unspecified route), prior to April 2024 (TRPHARM pipeline, April 2024)
- 29 Apr 2024 Phase-II clinical trials in Gouty arthritis (unspecified route), prior to April 2024 (TRPHARM pipeline, April 2024)
- 29 Apr 2024 Phase-III clinical trials in Pancreatitis (unspecified route), prior to April 2024 (TRPHARM pipeline, April 2024)